1 Nasal Delivery Technology - SNBL has discovered and developed an innovative nasal delivery technology, consisting of a muco-adhesive powder drug carrier designed for enhanced drug absorption and nasal delivery devices. The technology, now protected by international patent, is a versatile platform technology that can be applied to a broad range of drugs. Safety and efficacy of the technology have been proven in a number of clinical studies. For more information please visit www.snbl-nds.co.jp
2 Translational research - translates the findings of basic research into clinical applications quickly and efficiently, in order to bring new drugs to those in need as early as possible. SNBL utilizes its pre-clinical and clinical development facilities to develop value-adding technologies and provides them to the pharmaceutical and medical industry.
3 Drug reprofiling – one of Sosei’s development strategies that is based upon identifying new uses for existing drugs (either halted or marketed), or drug templates for which clinical development has been undertaken and the safety profile in humans confirmed.
4 APNT – (Activus Pure Nanoparticle Technology) unlike other nano-particle processing technologies, keeps compounds virtually free from contamination. At the same time, it can yield pharmaceutical ingredients with particle sizes ranging from 50 to 300nm levels. Thus, APNT enables the development of injections, ophthalmic solutions and inhalations with poorly soluble compounds where high purity is required.